Wells Fargo raised the firm’s price target on United Therapeutics to $325 from $309 and keeps an Overweight rating on the shares. The firm believes the market is pricing a downside scenario for United Therapeutics’ key Tyvaso franchise. Wells thinks the market is overlooking the PH-ILD market potential and historical experience of earlier line launches on United’s sales.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on UTHR:
- United Therapeutics price target lowered to $262 from $264 at Ladenburg
- United Therapeutics Sues FDA Over Liquidia’s Drug Expansion
- United Therapeutics commences litigation with FDA on drug review process
- United Therapeutics reports Q4 EPS $4.36, consensus $4.19
- Notable companies reporting before tomorrow’s open
